Inogen Inc (INGN) is Resumed by JP Morgan to Overweight

Inogen Inc (INGN) was Resumed by JP Morgan to “Overweight”. JP Morgan advised their investors in a research report released on Jul 13, 2016.

Many Wall Street Analysts have commented on Inogen Inc. Company shares were Reiterated by Stifel on May 10, 2016 to “Buy”, Firm has raised the Price Target to $ 52 from a previous price target of $46 .Company shares were Reiterated by Needham on May 10, 2016 to “Strong Buy”, Firm has raised the Price Target to $ 58 from a previous price target of $47 .

On the company’s financial health, Inogen Inc reported $0.11 EPS for the quarter, missing the analyst consensus estimate by $ -0.01 based on the information available during the earnings call on May 9, 2016. Analyst had a consensus of $0.12. The company had revenue of $43.00 million for the quarter, compared to analysts expectations of $41.89 million. The company’s revenue was up 27.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.08 EPS.

Inogen Inc closed down -0.09 points or -0.17% at $51.82 with 1,42,774 shares getting traded on Monday. Post opening the session at $51.63, the shares hit an intraday low of $51.3201 and an intraday high of $52.28 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

In a different news, on Jun 20, 2016, Raymond Huggenberger (CEO) sold 20,747 shares at $47.89 per share price. According to the SEC, on Jun 20, 2016, Matt Scribner (EVP, Operations) sold 4,102 shares at $47.91 per share price. On Apr 14, 2016, Brenton Taylor (EVP, Engineering) sold 6,500 shares at $48.00 per share price, according to the Form-4 filing with the securities and exchange commission.

Inogen Inc. is a medical technology company. The Company is engaged in developing manufacturing and marketing portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company offers Inogen One systems such as Inogen One G3 and G2 that concentrate the air around the patients to offer a single source of supplemental oxygen. The Inogen One G3 and G2 have up to 4.5 and five hours of battery life respectively. The Company’s Inogen One G2 is effective for nocturnal use.

Inogen Inc

Leave a Reply

Inogen Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Inogen Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.